Remedy for down's syndrome
Because there is no fundamental treatment for Down's syndrome, and participation in society is the ultimate goal, the present invention provides a remedy and method for treating Down's syndrome that improve congenital delayed psychomotor development, and promote improvement in the performance of daily activities and socialization. The present invention is directed to a therapeutic agent for Down's syndrome that contains an acetylcholinesterase inhibitor, a therapeutic agent for improving mental retardation in Down's syndrome, and an agent for improving daily activities of patients. Specifically, the acetylcholinesterase inhibitor is donepezil hydrochloride. More specifically, the present invention is directed to a therapeutic agent for Down's syndrome, a therapeutic agent for improving mental retardation in Down's syndrome, and an agent for improving daily activities of patients with an IQ of 48 or lower and/or patients aged 36 or younger.
1 . A therapeutic agent for Down's syndrome, comprising an acetylcholinesterase inhibitor.
2 . The therapeutic agent for Down's syndrome according to claim 1 , wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.
3 . The therapeutic agent for Down's syndrome according to claim 1 or 2 , wherein an intelligence quotient of a patient with Down's syndrome is 48 or lower.
4 . The therapeutic agent for Down's syndrome according to claim 1 , wherein an age of the patient with the Down's syndrome is 36 or younger.
5 . An agent for improving a daily activity of a Down's syndrome patient, comprising an acetylcholinesterase inhibitor.
6 . The agent for improving the daily activity according to claim 5 , wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.
7 . The agent for improving the daily activity according to claim 5 or 6 , wherein an intelligence quotient of the patient with the Down's syndrome is 48 or lower.
8 . The agent for improving the daily activity according to claim 5 , wherein an age of the patient with the Down's syndrome is 36 or younger.
9 . An agent for improving a mental retardation in Down's syndrome, comprising an acetylcholinesterase inhibitor.
10 . The agent for improving the mental retardation in Down's syndrome according to claim 9 , wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.
11 . The agent for improving the mental retardation in Down's syndrome according to claim 9 or 10 , wherein an intelligence quotient of a patient with the Down's syndrome is 48 or lower.
12 . The agent for improving the mental retardation in Down's syndrome according to claim 9 , wherein an age of the patient with the Down's syndrome is 36 or younger.
13 . An agent for mitigating or improving a symptom of rapid retrogression in Down's syndrome, comprising an acetylcholinesterase inhibitor.
14 . The agent for mitigating or improving the symptom of rapid retrogression in Down's syndrome according to claim 13 , wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.
15 . The agent for mitigating or improving the symptom of rapid retrogression in Down's syndrome according to claim 13 or 14 , wherein an intelligence quotient of a patient with the Down's syndrome is 48 or lower.
16 . The agent for mitigating or improving the symptom of rapid retrogression in Down's syndrome according to claim 13 , wherein an age of the patient with the Down's syndrome is 36 or younger.
17 . A method for treating Down's syndrome, comprising administering an acetylcholinesterase inhibitor to a patient with the Down's syndrome.
18 . The method for treating Down's syndrome according to claim 17 , wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.
19 . A method for improving a mental retardation or improving a daily activity of a Down's syndrome patient, comprising administering an acetylcholinesterase inhibitor to a patient with Down's syndrome.
20 . The method according to claim 19 , wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.
21 . A method for mitigating or improving symptoms of rapid retrogression in Down's syndrome, comprising administering an acetylcholinesterase inhibitor to a patient with Down's syndrome.
22 . The method for mitigating or improving symptoms of rapid retrogression in Down's syndrome according to claim 21 , wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.
23 . A composition for the treatment of Down's syndrome, comprising donepezil or a pharmaceutically acceptable salt thereof.
24 . A composition for the improvement of a daily activity of a Down's syndrome patient, comprising donepezil or a pharmaceutically acceptable salt thereof.
25 . A composition for the improvement of a mental retardation in Down's syndrome, comprising donepezil or a pharmaceutically acceptable salt thereof.
26 . A composition for mitigating or improving a symptom of rapid retrogression in Down's syndrome, comprising donepezil or a pharmaceutically acceptable salt thereof.